PT - JOURNAL ARTICLE AU - Qiao, Juanli AU - Xing, Rui AU - Fan, Zhiyuan AU - Zhou, Jing AU - Tian, Yuan AU - Qin, Yu AU - Liu, Zhaojun AU - Gu, Liankun AU - Ji, Jiafu AU - Lu, Youyong AU - Dawsey, Sanford M. AU - Wei, Wenqiang AU - Deng, Dajun TI - Characterization of the base-resolution common deletion region in <em>CDKN2A</em> gene in cancers and its biological and clinical significances AID - 10.1101/2021.09.16.21263412 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.16.21263412 4099 - http://medrxiv.org/content/early/2021/09/25/2021.09.16.21263412.short 4100 - http://medrxiv.org/content/early/2021/09/25/2021.09.16.21263412.full AB - Background Frequency of somatic copy number deletion of CDKN2A gene is upto 60% in human esophageal squamous cell cancer. However, it is unknown whether CDKN2A deletion could be a biomarker for esophageal squamous cell dysplasia (ESCdys).Methods Information on base-resolution common deletion region (CDR) for CDKN2A were extracted from published articles and confirmed with whole genome sequencing (WGS). A quantitative PCR targeted to the CDR (P16-Light) was established to detect CDKN2A copy number in ESCdys biopsies from patients (n=205) enrolled in a multicentre follow-up study.Results A 5.1-kb CDR from the CDKN2A/P16INK4A promoter to intron-2 was firstly characterized in 90% (83/92) of cancer cell lines and confirmed with WGS. The CDR covers CDKN2A exon-2 which is the essential coding exon for both P16INK4a and P14ARF. CDKN2A deletion was less common among 70 patients whose ESCdys regressed than among 135 patients whose ESCdys progressed or remained stable over a median of 37 months of follow-up (p&lt;0.0001).Conclusion Deletion of 5.1-kb CDR in CDKN2A gene could inactivate both P16INK4a and P14ARF and associate wtih prognosis of ESCdys.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02094105 and ChiCTR-EOC-17010553Clinical Protocols https://bmjopen.bmj.com/content/11/4/e042006.long Funding StatementThis work was supported by the Beijing Natural Science Foundation (grant number 7181002 to D.J.D.); Capital's Funds for Health Improvement and Research (grant number 2018-1-1021 to D.J.D.); and by the National Key R&amp;D Program of China (grant number 2016YFC0901404 to W.Q.W.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the China Cancer Foundation and the National Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College (Approval No. 16-171/1250)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetailed information on the base-resolution interstitial common deletion region in CDKN2A gene in 110 cancer samples was listed in Supplemental Table S1. Deidentified individual participant data that underlie the reported results was attached in the manuscript as Supplemental Table S2. Individual participant data will not be shared.